Share price movements
Today, Voyager Therapeutics (VYGR) issued a press release announcing a strategic collaboration with Neurocrine Biosciences (NBIX). The partnership focuses on the development and commercialization of its gene therapy programs, VY-AADC and VY-FXN01, in Parkinson’s disease and Friedreich’s ataxia, respectively. This news impressed investors and pushed up Voyager Therapeutics’ stock by almost 38.18% from its previous closing price on January 28 to $11.11.
Based on its closing price on January 28, the company reported returns of -2.66% last week, -13.27% last month, and -42.20% last quarter. Voyager Therapeutics also reported returns of -57.57% in the last half-year, -62.95% in the last year, and -14.47% year-to-date.
Voyager Therapeutics has a current market capitalization of $258.82 million. Micro-cap stocks generally pose a higher risk than the broader market or even large-cap stocks to retail investors.
Analysts’ recommendations and price targets for Voyager Therapeutics
The 12-month consensus analyst recommendation for Voyager Therapeutics on January 29 is a “buy.” The 12-month consensus price target for the company is $24.55, which is 120.38% higher than the company’s current trading price of $11.11.
Of the 11 analysts covering Voyager Therapeutics on January 29, six have rated the company a “strong buy,” three have rated it a “buy,” and two analysts have rated it a “hold.”